Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)

#2268

Introduction: SSA are the first line therapy in well differentiated pNET

Aim(s): To evaluate clinical effectiveness of Octreotide LAR in systemic initial therapy of advanced pancreatic (pNENs), based on progression free survival (PFS). A retrospective study.

Materials and methods: Overall data sets 374 patients with pNEN, 58 of them treated initially with Octreotide LAR 30mg 1x 4 weeks. Responses and AEs were evaluated after each of 4 weeks during follow-up. The primary objective (PFS) based on objective response rate (ORR) evaluated using CT/MRI after 6-month intervals. The clinical efficacy was based on PFS and time to subsequent death/PD, evaluated using Kaplan –Meier, radiological response and was classified according to RECIST 1.0.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kolasińska-Ćwikla A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Bednarczuk T, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Octreotide LAR therapy,